Stock VBS VECTUS BIOSYSTEMS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vectus Biosystems Limited

Equities

VBS

AU000000VBS9

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 08:31:11 2024-05-01 pm EDT 		5-day change 1st Jan Change
0.235 AUD -6.00% Intraday chart for Vectus Biosystems Limited -14.55% -21.67%
Feb. 23 Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
2023 Vectus Biosystems Limited Announces the Change of its Registered Office and Principal Place of Business Address CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 19.87 7.949 17.03 42.73 35.56 23.4
Enterprise Value (EV) 1 20.74 9.872 21.56 44.63 40.29 20.52
P/E ratio -7.68 x -4.98 x -5.66 x -8.88 x -8.23 x -6.12 x
Yield - - - - - -
Capitalization / Revenue 10,877 x 36,133 x 333 x 524 x 27.4 x 17.3 x
EV / Revenue 11,354 x 44,872 x 421 x 547 x 31 x 15.2 x
EV / EBITDA -5.22 x -4.2 x -8.16 x -12 x -12.3 x -6.42 x
EV / FCF -15.8 x -9.95 x -9.46 x -15 x -11.4 x -12.9 x
FCF Yield -6.32% -10% -10.6% -6.67% -8.8% -7.77%
Price to Book -8.81 x -2.13 x -3.02 x -15.1 x -10.1 x 6.64 x
Nbr of stocks (in thousands) 23,380 23,380 23,655 31,655 36,101 53,190
Reference price 2 0.8500 0.3400 0.7200 1.350 0.9850 0.4400
Announcement Date 9/28/18 9/30/19 8/31/20 8/31/21 9/29/22 8/30/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 0.001827 0.00022 0.0512 0.0816 1.3 1.355
EBITDA 1 -3.973 -2.35 -2.644 -3.706 -3.28 -3.196
EBIT 1 -3.993 -2.373 -2.663 -3.723 -3.3 -3.243
Operating Margin -218,553.04% -1,078,662.27% -5,203.31% -4,563.52% -253.85% -239.44%
Earnings before Tax (EBT) 1 -4.016 -2.496 -3.38 -4.798 -3.994 -3.449
Net income 1 -2.587 -1.596 -2.996 -4.283 -3.994 -3.449
Net margin -141,614.45% -725,581.82% -5,853.3% -5,248.89% -307.19% -254.62%
EPS 2 -0.1107 -0.0683 -0.1273 -0.1520 -0.1197 -0.0719
Free Cash Flow 1 -1.312 -0.9918 -2.279 -2.975 -3.547 -1.595
FCF margin -71,797.04% -450,805.91% -4,452.58% -3,646.62% -272.8% -117.78%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/28/18 9/30/19 8/31/20 8/31/21 9/29/22 8/30/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 0.87 1.92 4.53 1.89 4.73 -
Net Cash position 1 - - - - - 2.88
Leverage (Debt/EBITDA) -0.219 x -0.818 x -1.714 x -0.5101 x -1.443 x -
Free Cash Flow 1 -1.31 -0.99 -2.28 -2.98 -3.55 -1.6
ROE (net income / shareholders' equity) 242% 53.3% 63.9% 101% 147% 65,755%
ROA (Net income/ Total Assets) -544% -760% -104% -51.5% -37.8% -47.3%
Assets 1 0.4753 0.2101 2.873 8.319 10.57 7.287
Book Value Per Share 2 -0.1000 -0.1600 -0.2400 -0.0900 -0.1000 0.0700
Cash Flow per Share 2 0 0 0.1100 0.1800 0.0400 0.0600
Capex - - - - 0.02 0.02
Capex / Sales - - - - 1.62% 1.26%
Announcement Date 9/28/18 9/30/19 8/31/20 8/31/21 9/29/22 8/30/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VECTUS BIOSYSTEMS LIMITED Stock Vectus Biosystems Limited
-21.67% 8.27M
MODERNA, INC. Stock Moderna, Inc.
+21.76% 47.9B
LONZA GROUP AG Stock Lonza Group AG
+46.62% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.18% 40.7B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.19% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.87% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.32% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.04% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.47% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VBS Stock
  4. Financials Vectus Biosystems Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW